Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Twelve Seas Investment Company (TWLVU)
Kensington Capital Acquisition (KCAC.U)
African Gold Acquisition (AGAC.U)
Fusion Acquisition II (FSNB.U)
Mcap Acquisition (MACQU)
Silverbox Engaged Merger I (SBEAU)
Ibere Pharmaceuticals (IBERU)
Freedom Acquisition I (FACT.U)
Arya Sciences Acquisition IV (ARYD)
Warrior Technologies Acquisition Company (WARR.U)
Austerlitz Acquisition Corporation II (ASZ.U)
Austerlitz Acquisition Corporation I (AUS.U)
Leo Holdings III Corp. (LIII.U)
Upcoming IPO
Property Solutions Acquisition II (PSAGU)
Nightdragon Acquisition (NDACU)
Roblox Corporation (RBLX)
Afc Gamma, Inc. (AFCG)
Roth Ch Acquisition III (ROCRU)
Oscar Health, Inc. (OSCR)
Innovage Holding Corp (INNV)
Priced IPO
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
Global Internet of People (SDH)
Baosheng Media Group Holdings (BAOS)
More companies

Biophytis SA (BPTS)

Sector - Healthcare

Price chart

-1.49%
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world. Their lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases. Sarconeos (BIO101) is a plant-derived pharmaceutical-grade purified 20-hydroxyecdysone. They have completed preclinical studies, including chronic toxicology and safety pharmacology studies, and a Phase 1 clinical trial in healthy human volunteers, which are necessary for pursuing further clinical development of Sarconeos (BIO101). Their early data suggests that Sarconeos (BIO101) stimulates biological resilience and muscle metabolism in cellular models, and preserves strength, mobility and respiratory capacity in animal models of certain neuromuscular diseases. While they are still in the early stages of development, they believe that these results support further investigation and clinical development of Sarconeos (BIO101) in patients with certain neuromuscular and respiratory diseases.
Industry
Pharmaceuticals
CEO CFO
Stanislas Veillet Daniel Schneiderman
Employees Founded
23 2006

Contacts

Address: Sorbonne University—BC 9, Bâtiment A 4ème étage 4 place Jussieu 75001 Paris, France

Telephone: +33 1 44 27 23 00

Web page: http://www.biophytis.com

IPO information

Expected Date 2/10/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 8.8
Shares Revised (MM) 1.2
Expected offer amount (MM) $15
Realized offer amount(MM) $20.1

Financial Data (last reporting year)

Market Cap (MM) $186.29
Revenues (MM) $0
Net Income (Loss) (MM) $-20.7

Voting

What do you think will happen with the BPTS share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: H.C. Wainwright & Co.

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
H.C. Wainwright & Co.
CO-Managers
Invest Securities S.A.

Sector: Healthcare

Tweets about $BPTS

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats